News
Writing in JAMA, four former government officials warn that the Trump administration’s involvement in delaying the approval ...
2d
Stocktwits on MSNModerna, Pfizer, Novavax Draw Bearish Buzz Ahead Of CDC Panel With Vaccine SkepticsRetail investor chatter around vaccine makers Novavax, Moderna, and Pfizer rose on Wednesday, ahead of a closely watched CDC ...
The Centers for Disease Control and Prevention's vaccine advisory committee is set to meet for the first time since Health ...
The meeting, scheduled for June 25-26, will review existing data and vote on RSV and influenza vaccines, along with ...
Shares of San Diego-based Cidara Therapeutics Inc. (NASDAQ:CDTX) were trading at $40.41, up $19.39, or 92%, on positive top-line results from its randomized, double-blind, placebo-controlled phase IIb ...
Novavax (NVAX) stock jumped on Wednesday after the vaccine maker released results from a Phase 3 clinical trial of its COVID-19-Influenza Combination (CIC) and stand-alone flu vaccine. The initial ...
15d
Zacks Investment Research on MSNNovavax's COVID-Flu Combo Shot Shows Strong Immune ResponseNovavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.
Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 and older.
Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in ...
The Gaithersburg, Md., biotechnology company said Wednesday that results of the initial cohort of vaccines showed both the Covid-19-influenza combination and flu-vaccine candidates induced immune ...
Summary. Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating their protein-based vaccine technology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results